Top

Published in:

14-06-2022 | Non-Thematic Review

Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective

Authors: Kristian M. Hargadon, Travis B. Goodloe III, Nathaniel D. Lloyd

Published in: Cancer and Metastasis Reviews | Issue 4/2022

Abstract

Epigenetic regulation of gene expression is a fundamental determinant of molecular and cellular function, and epigenetic reprogramming in the context of cancer has emerged as one of the key enabling characteristics associated with acquisition of the core hallmarks of this disease. As such, there has been renewed interest in studying the role of transcription factors as epigenetic regulators of gene expression in cancer. In this review, we discuss the current state of knowledge surrounding the oncogenic functions of FOXC2, a transcription factor that frequently becomes dysregulated in a variety of cancer types. In addition to highlighting the clinical impact of aberrant FOXC2 activity in cancer, we discuss mechanisms by which this transcription factor becomes dysregulated in both tumor and tumor-associated cells, placing particular emphasis on the ways in which FOXC2 promotes key hallmarks of cancer progression. Finally, we bring attention to important issues related to the oncogenic dysregulation of FOXC2 that must be addressed going forward in order to improve our understanding of FOXC2-mediated cancer progression and to guide prognostic and therapeutic applications of this knowledge in clinical settings.

Miura, N., Wanaka, A., Tohyama, M., & Tanaka, K. (1993). MFH-1, a new member of the fork head domain family, is expressed in developing mesenchyme. FEBS Letters, 326(1–3), 171–176. https://doi.org/10.1016/0014-5793(93)81785-XCrossRef

Xue, Y., Cao, R., Nilsson, D., Chen, S., Westergren, R., Hedlund, E. M., et al. (2008). FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proceedings of the National Academy of Sciences of the United States of America, 105(29), 10167–10172. https://doi.org/10.1073/pnas.0802486105CrossRef

Hader, C., Marlier, A., & Cantley, L. (2010). Mesenchymal-epithelial transition in epithelial response to injury: The role of Foxc2. Oncogene, 29(7), 1031–1040. https://doi.org/10.1038/onc.2009.397CrossRef

Motojima, M., Kume, T., & Matsusaka, T. (2017). Foxc1 and Foxc2 are necessary to maintain glomerular podocytes. Experimental Cell Research, 352(2), 265–272. https://doi.org/10.1016/J.YEXCR.2017.02.016CrossRef

Cederberg, A., Gronning, L. M., Ahrén, B., Taskén, K., Carlsson, P., & Enerbäck, S. (2001). FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. Cell, 106(5), 563–573. https://doi.org/10.1016/S0092-8674(01)00474-3CrossRef

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRef

Hanahan, D. (2022). Hallmarks of Cancer: New dimensions. Cancer Discovery, 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059CrossRef

Grønning, L. M., Cederberg, A., Miura, N., Enerbäck, S., & Taskén, K. (2002). Insulin and TNF alpha induce expression of the forkhead transcription factor gene Foxc2 in 3T3-L1 adipocytes via PI3K and ERK 1/2-dependent pathways. Molecular Endocrinology, 16(4), 873–883. https://doi.org/10.1210/MEND.16.4.0803CrossRef

Paranjape, A. N., Soundararajan, R., Werden, S. J., Joseph, R., Taube, J. H., Liu, H., et al. (2016). Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene, 35(46), 5963–5976. https://doi.org/10.1038/onc.2015.498CrossRef

10.

Christofides, A., Papagregoriou, G., Dweep, H., Makrides, N., Gretz, N., Felekkis, K., & Deltas, C. (2020). Evidence for miR-548c-5p regulation of FOXC2 transcription through a distal genomic target site in human podocytes. Cellular and Molecular Life Sciences, 77(12), 2441–2459. https://doi.org/10.1007/S00018-019-03294-ZCrossRef

11.

Ge, J., Li, J., Na, S., Wang, P., Zhao, G., & Zhang, X. (2019). miR-548c-5p inhibits colorectal cancer cell proliferation by targeting PGK1. Journal of Cellular Physiology, 234(10), 18872–18878. https://doi.org/10.1002/JCP.28525CrossRef

12.

He, S. Z., & Wang, Q. (2020). MicroRNA-548c-5p inhibits the proliferation of breast cancer cells through regulating Wnt/β-catenin signaling pathway. European Review for Medical and Pharmacological Sciences, 24(7), 3795–3804. https://doi.org/10.26355/EURREV_202004_20845

13.

Chen, C., Chen, Q., Wu, J., & Zou, H. (2021). H3K27ac-induced FOXC2-AS1 accelerates tongue squamous cell carcinoma by upregulating E2F3. Journal of OralPpathology & Medicine, 50(10), 1018–1030. https://doi.org/10.1111/JOP.13232CrossRef

14.

Lim, Y. H., Ryu, J., Kook, H., & Kim, Y. K. (2020). Identification of long noncoding RNAs involved in differentiation and survival of vascular smooth muscle cells. Molecular Therapy Nucleic Acids, 22, 209–221. https://doi.org/10.1016/J.OMTN.2020.08.032CrossRef

15.

Zhang, C.-L., Zhu, K.-P., & Ma, X.-L. (2017). Antisense lncRNA FOXC2-AS1 promotes doxorubicin resistance in osteosarcoma by increasing the expression of FOXC2. Cancer Letters, 396, 66–75. https://doi.org/10.1016/j.canlet.2017.03.018CrossRef

16.

Pan, K., & Xie, Y. (2020). LncRNA FOXC2-AS1 enhances FOXC2 mRNA stability to promote colorectal cancer progression via activation of Ca 2+-FAK signal pathway. Cell Death & Disease, 11(6), 434. https://doi.org/10.1038/S41419-020-2633-7CrossRef

17.

Yan, J., Liu, J., Huang, Z., Huang, W., & Lv, J. (2021). FOXC2-AS1 stabilizes FOXC2 mRNA via association with NSUN2 in gastric cancer cells. Human Cell, 34(6), 1755–1764. https://doi.org/10.1007/S13577-021-00583-3CrossRef

18.

Gong, Y. Q., Ni, J. L., Fang, Q., & Li, T. (2020). MiR-1231 enhances docetaxel sensitivity to gallbladder carcinoma cells by downregulating FOXC2. European Review for Medical and Pharmacological Sciences, 24(23), 12116–12123. https://doi.org/10.26355/EURREV_202012_24000

19.

Yan, M., Gao, H., Lv, Z., Liu, Y., Zhao, S., Gong, W., & Liu, W. (2020). Circular RNA PVT1 promotes metastasis via regulating of miR-526b/FOXC2 signals in OS cells. Journal of Cellular and Molecular Medicine, 24(10), 5593–5604. https://doi.org/10.1111/JCMM.15215CrossRef

20.

Weng, Z., Peng, J., Wu, W., Zhang, C., Zhao, J., & Gao, H. (2021). Downregulation of PART1 inhibits proliferation and differentiation of Hep3B cells by targeting hsa-miR-3529-3p/FOXC2 axis. Journal of Oncology, 2021, 7792223. https://doi.org/10.1155/2021/7792223CrossRef

21.

Liu, H., Zhang, Z., Han, Y., Fan, A., Liu, H., Zhang, X., et al. (2021). The FENDRR/FOXC2 axis contributes to multidrug resistance in gastric cancer and correlates with poor prognosis. Frontiers in Oncology, 11, 634579. https://doi.org/10.3389/FONC.2021.634579CrossRef

22.

Bi, Y., Guo, S., Xu, X., Kong, P., Cui, H., Yan, T., et al. (2020). Decreased ZNF750 promotes angiogenesis in a paracrine manner via activating DANCR/miR-4707-3p/FOXC2 axis in esophageal squamous cell carcinoma. Cell Death & Disease, 11(4), 296. https://doi.org/10.1038/S41419-020-2492-2CrossRef

23.

Shen, X., Zhao, K., Xu, L., Cheng, G., Zhu, J., Gan, L., et al. (2021). YTHDF2 inhibits gastric cancer cell growth by regulating FOXC2 signaling pathway. Frontiers in Genetics, 11, 592042. https://doi.org/10.3389/FGENE.2020.592042CrossRef

24.

Missaglia, S., Tavian, D., Michelini, S., Maltese, P. E., Bonanomi, A., & Bertelli, M. (2021). Imbalance between expression of FOXC2 and its lncRNA in lymphedema-distichiasis caused by frameshift mutations. Genes, 12(5), 650. https://doi.org/10.3390/GENES12050650CrossRef

25.

Golden, D., & Cantley, L. G. (2015). Casein kinase 2 prevents mesenchymal transformation by maintaining Foxc2 in the cytoplasm. Oncogene, 34(36), 4702–4712. https://doi.org/10.1038/onc.2014.395CrossRef

26.

Ivanov, K. I., Agalarov, Y., Valmu, L., Samuilova, O., Liebl, J., Houhou, N., et al. (2013). Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells. Molecular and Cellular Biology, 33(19), 3749–3761. https://doi.org/10.1128/MCB.01387-12CrossRef

27.

Werden, S. J., Sphyris, N., Sarkar, T. R., Paranjape, A. N., LaBaff, A. M., Taube, J. H., et al. (2016). Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth. Oncogene, 35(46), 5977–5988. https://doi.org/10.1038/onc.2016.203CrossRef

28.

Danciu, T. E., Chupreta, S., Cruz, O., Fox, J. E., Whitman, M., & Iñiguez-Lluhí, J. A. (2012). Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2. The Journal of Biological Chemistry, 287(22), 18318–18329. https://doi.org/10.1074/JBC.M112.339424CrossRef

29.

Ren, Y. H., Liu, K. J., Wang, M., Yu, Y. N., Yang, K., Chen, Q., et al. (2014). De-SUMOylation of FOXC2 by SENP3 promotes the epithelial-mesenchymal transition in gastric cancer cells. Oncotarget, 5(16), 7093–7104. https://doi.org/10.18632/ONCOTARGET.2197

30.

Wu, D., Ke, Y., Xiao, R., Liu, J., Li, Q., & Wang, Y. (2021). Long non-coding RNA GClnc1 knockdown suppresses progression of epithelial ovarian cancer by recruiting FOXC2 to disrupt the NOTCH1/NF-κB/Snail pathway. Experimental Cell Research, 399(1). https://doi.org/10.1016/J.YEXCR.2020.112422

31.

Zhou, P., Li, Y., Di, R., Yang, Y., Meng, S., Song, F., & Ma, L. (2019). H19 and Foxc2 synergistically promotes osteogenic differentiation of BMSCs via Wnt-β-catenin pathway. Journal of Cellular Physiology, 234(8), 13799–13806. https://doi.org/10.1002/JCP.28060CrossRef

32.

Kume, T., & Shackour, T. (2018). Meta-analysis of the likelihood of FOXC2 expression in earlyand late-stage tumors. Oncotarget, 9(70), 33396–33402. https://doi.org/10.18632/oncotarget.26087

33.

Li, Y., Yang, W., Yang, Q., & Zhou, S. (2012). Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype. Histology and Histopathology, 27(4), 475–84. https://doi.org/10.14670/HH-27.475

34.

Li, Q., Wu, J., Wei, P., Xu, Y., Zhuo, C., Wang, Y., et al. (2015). Overexpression of forkhead Box C2 promotes tumor metastasis and indicates poor prognosis in colon cancer via regulating epithelial-mesenchymal transition. American Journal of Cancer Research, 5(6), 2022–34. http://www.ncbi.nlm.nih.gov/pubmed/26269761

35.

Jiang, W., Fan, H., Qian, C., Ding, J., Wang, Q., & Pang, X. (2016). Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression. BMC Cancer, 16(1), 16. https://doi.org/10.1186/s12885-016-2056-0CrossRef

36.

Shimoda, Y., Ubukata, Y., Handa, T., Yokobori, T., Watanabe, T., Gantumur, D., et al. (2018). High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma. BMC Cancer, 18(1), 597. https://doi.org/10.1186/s12885-018-4503-6CrossRef

37.

Børretzen, A., Gravdal, K., Haukaas, S. A., Beisland, C., Akslen, L. A., & Halvorsen, O. J. (2019). FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. The Journal of Pathology: Clinical Research, 5(4), 272–286. https://doi.org/10.1002/cjp2.142CrossRef

38.

Zhu, J.-L., Song, Y.-X., Wang, Z.-N., Gao, P., Wang, M.-X., Dong, Y.-L., et al. (2013). The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology, 62(7), 1038–1048. https://doi.org/10.1111/his.12132CrossRef

39.

Xu, B., Tian, Y., & Liu, L. (2020). Meta-analysis of the prognostic significance of FOXC2 in various tumors. The Journal of International Medical Research, 48(3), 300060519891648. https://doi.org/10.1177/0300060519891648CrossRef

40.

Hargadon, K. M., Győrffy, B., & Strong, E. W. (2021). The prognostic significance of FOXC2 gene expression in cancer: A comprehensive analysis of RNA-seq data from the cancer genome atlas. Cancer genetics, 254–255, 58–64. https://doi.org/10.1016/J.CANCERGEN.2021.02.005CrossRef

41.

Nishida, N., Mimori, K., Yokobori, T., Sudo, T., Tanaka, F., Shibata, K., et al. (2011). FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Annals of Surgical Oncology, 18(2), 535–542. https://doi.org/10.1245/s10434-010-1274-yCrossRef

42.

Wang, Y.-W., Yin, C.-L., Zhang, H.-Y., Hao, J., Yang, Y.-Y., Liao, H., & Jiao, B.-H. (2014). High expression of forkhead box protein C2 is related to poor prognosis in human gliomas. Asian Pacific Journal of Cancer Prevention, 15(24), 10621–10625. https://doi.org/10.7314/apjcp.2014.15.24.10621CrossRef

43.

Hargadon, K. M., Györffy, B., Strong, E. W., Tarnai, B. D., Thompson, J. C., Bushhouse, D. Z., et al. (2019). The FOXC2 transcription factor promotes melanoma outgrowth and regulates expression of genes associated with drug resistance and interferon responsiveness. Cancer Genomics & Proteomics, 16(6), 491–503. https://doi.org/10.21873/cgp.20152

44.

Yang, H., Chen, T., Xu, S., Zhang, S., & Zhang, M. (2019). Long noncoding RNA FOXC2-AS1 predicts poor survival in breast cancer patients and promotes cell proliferation. Oncology Research, 27(2), 219–226. https://doi.org/10.3727/096504018X15213126075068CrossRef

45.

Xu, D. F., Tao, X. H., Yu, Y., Teng, Y., Huang, Y. M., Ma, J. W., & Fan, Y. B. (2020). LncRNA FOXC2-AS1 stimulates proliferation of melanoma via silencing p15 by recruiting EZH2. European Review for Medical and Pharmacological Sciences, 24(17), 8940–8946. https://doi.org/10.26355/EURREV_202009_22835

46.

Cui, Y.-M., Jiang, D., Zhang, S.-H., Wu, P., Ye, Y.-P., Chen, C.-M., et al. (2014). FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways. Cancer Letters, 353(1), 87–94. https://doi.org/10.1016/j.canlet.2014.07.008CrossRef

47.

RS, N., & P, H. (2014). FoxO3a and disease progression. World Journal of Biological Chemistry, 5(3), 346. https://doi.org/10.4331/WJBC.V5.I3.346CrossRef

48.

Park, S. J., Gadi, J., Cho, K. W., Kim, K. J., Kim, S. H., Jung, H. S., & Lim, S. K. (2011). The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin β1 expression. Bone, 49(3), 428–438. https://doi.org/10.1016/J.BONE.2011.05.012CrossRef

49.

Pan, J., Yang, Q., Shao, J., Zhang, L., Ma, J., Wang, Y., et al. (2016). Cyclooxygenase-2 induced β1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway. Scientific Reports, 6, 33823. https://doi.org/10.1038/srep33823CrossRef

50.

Shibue, T., & Weinberg, R. A. (2009). Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proceedings of the National Academy of Sciences of the United States of America, 106(25), 10290–10295. https://doi.org/10.1073/PNAS.0904227106CrossRef

51.

Cui, L., Dang, S., Qu, J., Mao, Z., Wang, X., Zhang, J., & Chen, J. (2016). FOXC2 is up-regulated in pancreatic ductal adenocarcinoma and promotes the growth and migration of cancer cells. Tumour Biology, 37(7), 8579–8585. https://doi.org/10.1007/S13277-015-4607-4CrossRef

52.

Gozo, M. C., Aspuria, P. J., Cheon, D. J., Walts, A. E., Berel, D., Miura, N., et al. (2013). Foxc2 induces Wnt4 and Bmp4 expression during muscle regeneration and osteogenesis. Cell Death and Differentiation, 20(8), 1031. https://doi.org/10.1038/CDD.2013.34CrossRef

53.

Li, W., Fu, X., Liu, R., Wu, C., Bai, J., Xu, Y., et al. (2013). FOXC2 often overexpressed in glioblastoma enhances proliferation and invasion in glioblastoma cells. Oncology Research, 21(2), 111–120. https://doi.org/10.3727/096504013X13814233062171CrossRef

54.

Zheng, C.-H., Quan, Y., Li, Y.-Y., Deng, W.-G., Shao, W.-J., & Fu, Y. (2014). Expression of transcription factor FOXC2 in cervical cancer and effects of silencing on cervical cancer cell proliferation. Asian Pacific Journal of Cancer Prevention, 15(4), 1589–1595. https://doi.org/10.7314/apjcp.2014.15.4.1589CrossRef

55.

Gozo, M. C., Jia, D., Aspuria, P.-J., Cheon, D.-J., Miura, N., Walts, A. E., et al. (2016). FOXC2 augments tumor propagation and metastasis in osteosarcoma. Oncotarget, 7(42), 68792–68802. https://doi.org/10.18632/oncotarget.11990

56.

Li, C., Ding, H., Tian, J., Wu, L., Wang, Y., Xing, Y., & Chen, M. (2016). Forkhead box protein C2 (FOXC2) promotes the resistance of human ovarian cancer cells to cisplatin in vitro and in vivo. Cellular Physiology and Biochemistry, 39(1), 242–252. https://doi.org/10.1159/000445620CrossRef

57.

Yang, C., Cui, X., Dai, X., & Liao, W. (2016). Downregulation of Foxc2 enhances apoptosis induced by 5-fluorouracil through activation of MAPK and AKT pathways in colorectal cancer. Oncology Letters, 11(2), 1549–1554. https://doi.org/10.3892/ol.2016.4097CrossRef

58.

Gan, L., Liu, Z., Jin, W., Zhou, Z., & Sun, C. (2015). Foxc2 enhances proliferation and inhibits apoptosis through activating Akt/mTORC1 signaling pathway in mouse preadipocytes. Journal of Lipid Research, 56(8), 1471–1480. https://doi.org/10.1194/jlr.M057679CrossRef

59.

Lambert, A. W., & Weinberg, R. A. (2021). Linking EMT programmes to normal and neoplastic epithelial stem cells. Nature Reviews Cancer, 21(5), 325–338. https://doi.org/10.1038/S41568-021-00332-6CrossRef

60.

Mani, S. A., Yang, J., Brooks, M., Schwaninger, G., Zhou, A., Miura, N., A., et al. (2007). Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proceedings of the National Academy of Sciences of the United States of America, 104(24), 10069–10074. https://doi.org/10.1073/pnas.0703900104CrossRef

61.

Li, C., Ding, H., Tian, J., Wu, L., Wang, Y., Xing, Y., & Chen, M. (2016). Forkhead box protein C2 promotes epithelial-mesenchymal transition, migration and invasion in cisplatin-resistant human ovarian cancer cell line (SKOV3/CDDP). Cellular Physiology and Biochemistry, 39(3), 1098–1110. https://doi.org/10.1159/000447818CrossRef

62.

Chen, J., Rong, X., Liu, X., Zheng, D., Rong, X., Chen, F., et al. (2020). FOXC2 is a prognostic biomarker and contributes to the growth and invasion of human hepatocellular carcinoma. Cancer Cell International, 20(1). https://doi.org/10.1186/s12935-020-01265-0

63.

Mortazavi, F., An, J., Dubinett, S., & Rettig, M. (2010). p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Molecular Cancer Research, 8(5), 762–774. https://doi.org/10.1158/1541-7786.MCR-10-0004CrossRef

64.

Pham, T. N. D., Perez White, B. E., Zhao, H., Mortazavi, F., & Tonetti, D. A. (2017). Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin. BMC Cancer, 17(1), 832. https://doi.org/10.1186/s12885-017-3827-yCrossRef

65.

Aster, J. C., Pear, W. S., & Blacklow, S. C. (2017). The varied roles of Notch in cancer. Annual Review of Pathology, 12, 245–275. https://doi.org/10.1146/ANNUREV-PATHOL-052016-100127CrossRef

66.

Kwon, O. J., Zhang, L., Wang, J., Su, Q., Feng, Q., Zhang, X. H. F., et al. (2016). Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. The Journal of Clinical Investigation, 126(7), 2626–2641. https://doi.org/10.1172/JCI84637CrossRef

67.

Hayashi, H., Sano, H., Seo, S., & Kume, T. (2008). The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. The Journal of Biological Chemistry, 283(35), 23791–23800. https://doi.org/10.1074/jbc.M800190200CrossRef

68.

Hamidi, H., & Ivaska, J. (2018). Every step of the way: Integrins in cancer progression and metastasis. Nature Reviews Cancer, 18(9), 533–548. https://doi.org/10.1038/s41568-018-0038-zCrossRef

69.

Su, C. Y., Li, J. Q., Zhang, L. L., Wang, H., Wang, F. H., Tao, Y. W., et al. (2020). The biological functions and clinical applications of integrins in cancers. Frontiers in Pharmacology, 11, 579068. https://doi.org/10.3389/FPHAR.2020.579068CrossRef

70.

Watanabe, A., Suzuki, H., Yokobori, T., Altan, B., Kubo, N., Araki, K., et al. (2013). Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis. Cancer Science, 104(11), 1427–1432. https://doi.org/10.1111/CAS.12249CrossRef

71.

Zhang, Y., & Zhang, Y. (2018). Forkhead box C2 promotes the invasion ability of human trophoblast cells through Hedgehog (Hh) signaling pathway. Cell Biology International, 42(7), 859–866. https://doi.org/10.1002/CBIN.10953CrossRef

72.

Cui, Y.-M., Jiao, H.-L., Ye, Y.-P., Chen, C.-M., Wang, J.-X., Tang, N., et al. (2015). FOXC2 promotes colorectal cancer metastasis by directly targeting MET. Oncogene, 34(33), 4379–4390. https://doi.org/10.1038/onc.2014.368CrossRef

73.

Sarkar, T. R., Battula, V. L., Werden, S. J., Vijay, G. V., Ramirez-Peña, E. Q., Taube, J. H., et al. (2015). GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer. Oncogene, 34(23), 2958–2967. https://doi.org/10.1038/ONC.2014.245CrossRef

74.

Hollier, B. G., Tinnirello, A. A., Werden, S. J., Evans, K. W., Taube, J. H., Sarkar, T. R., et al. (2013). FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Research, 73(6), 1981–1992. https://doi.org/10.1158/0008-5472.CAN-12-2962CrossRef

75.

Davis, K. E., Moldes, M., & Farmer, S. R. (2004). The forkhead transcription factor FoxC2 inhibits white adipocyte differentiation. Journal of Biological Chemistry, 279(41), 42453–42461. https://doi.org/10.1074/JBC.M402197200CrossRef

76.

Kume, T. (2009). The cooperative roles of Foxc1 and Foxc2 in cardiovascular development. Advances in Experimental Medicine and Biology, 665, 63–77. https://doi.org/10.1007/978-1-4419-1599-3_5CrossRef

77.

Kume, T. (2008). Foxc2 transcription factor: A newly described regulator of angiogenesis. Trends in Cardiovascular Medicine, 18(6), 224–228. https://doi.org/10.1016/J.TCM.2008.11.003CrossRef

78.

Lin, Y., Mckinnon, K. E., Ha, S. W., & Beck, G. R. (2015). Inorganic phosphate induces cancer cell mediated angiogenesis dependent on forkhead box protein C2 (FOXC2) regulated osteopontin expression. Molecular Carcinogenesis, 54(9), 926–934. https://doi.org/10.1002/MC.22153CrossRef

79.

Sano, H., Leboeuf, J. P., Novitskiy, S. V., Seo, S., Zaja-Milatovic, S., Dikov, M. M., & Kume, T. (2010). The Foxc2 transcription factor regulates tumor angiogenesis. Biochemical and Biophysical Research Communications, 392(2), 201–206. https://doi.org/10.1016/j.bbrc.2010.01.015CrossRef

80.

Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., et al. (1998). Tumor induction of VEGF promoter activity in stromal cells. Cell, 94(6), 715–725. https://doi.org/10.1016/S0092-8674(00)81731-6CrossRef

81.

Kume, T. (2012). The role of FoxC2 transcription factor in tumor angiogenesis. Journal of Oncology, 2012, 204593. https://doi.org/10.1155/2012/204593CrossRef

82.

Yao, H., & He, S. (2021). Multi-faceted role of cancer-associated adipocytes in the tumor microenvironment (Review). Molecular Medicine Reports, 24(6), 866. https://doi.org/10.3892/MMR.2021.12506CrossRef

83.

Hayashi, H., & Kume, T. (2008). Forkhead transcription factors regulate expression of the chemokine receptor CXCR4 in endothelial cells and CXCL12-induced cell migration. Biochemical and Biophysical Research Communications, 367(3), 584–589. https://doi.org/10.1016/J.BBRC.2007.12.183CrossRef

84.

Hayashi, H., & Kume, T. (2008). Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS ONE, 3(6), e2401. https://doi.org/10.1371/JOURNAL.PONE.0002401CrossRef

85.

Xia, S., Menden, H. L., Korfhagen, T. R., Kume, T., & Sampath, V. (2018). Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling. The Journal of Physiology, 596(8), 1397–1417. https://doi.org/10.1113/JP275453CrossRef

86.

Fujita, H., Kang, M., Eren, M., Gleaves, L. A., Vaughan, D. E., & Kume, T. (2006). Foxc2 is a common mediator of insulin and transforming growth factor β signaling to regulate plasminogen activator inhibitor type I gene expression. Circulation Research, 98(5), 626–634. https://doi.org/10.1161/01.RES.0000207407.51752.3cCrossRef

87.

Takayama, Y., Hattori, N., Hamada, H., Masuda, T., Omori, K., Akita, S., et al. (2016). Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma. Cancer Research, 76(11), 3285–3294. https://doi.org/10.1158/0008-5472.CAN-15-1796CrossRef

88.

Sphyris, N., King, C., Hoar, J., Werden, S. J., Vijay, G. V., Miura, N., et al. (2021). Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth. Oncotarget, 12(8), 823–844. https://doi.org/10.18632/ONCOTARGET.27940

89.

Hernández de la Cruz, O. N., López-González, J. S., García-Vázquez, R., Salinas-Vera, Y. M., Muñiz-Lino, M. A., Aguilar-Cazares, D., et al. (2020). Regulation networks driving vasculogenic mimicry in solid tumors. Frontiers in Oncology, 9, 1419. https://doi.org/10.3389/FONC.2019.01419CrossRef

90.

Wei, X., Chen, Y., Jiang, X., Peng, M., Liu, Y., Mo, Y., et al. (2021). Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Molecular Cancer, 20(1), 7. https://doi.org/10.1186/S12943-020-01288-1CrossRef

91.

Fang, J., Dagenais, S. L., Erickson, R. P., Arlt, M. F., Glynn, M. W., Gorski, J. L., et al. (2000). Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. American Journal of Human Genetics, 67(6), 1382–1388. https://doi.org/10.1086/316915CrossRef

92.

Tavian, D., Missaglia, S., Maltese, P. E., Michelini, S., Fiorentino, A., Ricci, M., et al. (2016). FOXC2 disease-mutations identified in lymphedema-distichiasis patients cause both loss and gain of protein function. Oncotarget, 7(34), 54228–54239. https://doi.org/10.18632/ONCOTARGET.9797

93.

González-Loyola, A., Bovay, E., Kim, J., Lozano, T. W., Sabine, A., Renevey, F., et al. (2021). FOXC2 controls adult lymphatic endothelial specialization, function, and gut lymphatic barrier preventing multiorgan failure. Science Advances, 7(29), eabf4335. https://doi.org/10.1126/SCIADV.ABF4335

94.

Liebl, J., Zhang, S., Moser, M., Agalarov, Y., Demir, C. S., Hager, B., et al. (2015). Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2. Nature Communications, 6, 7274. https://doi.org/10.1038/NCOMMS8274CrossRef

95.

Kanady, J. D., Munger, S. J., Witte, M. H., & Simon, A. M. (2015). Combining Foxc2 and Connexin37 deletions in mice leads to severe defects in lymphatic vascular growth and remodeling. Developmental Biology, 405(1), 33–46. https://doi.org/10.1016/J.YDBIO.2015.06.004CrossRef

96.

Fatima, A., Wang, Y., Uchida, Y., Norden, P., Liu, T., Culver, A., et al. (2016). Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivation. The Journal of Clinical Investigation, 126(7), 2437–2451. https://doi.org/10.1172/JCI80465CrossRef

97.

Cha, B., Geng, X., Mahamud, M. R., Fu, J., Mukherjee, A., Kim, Y., et al. (2016). Mechanotransduction activates canonical Wnt/β-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves. Genes and Development, 30(12), 1454–1469. https://doi.org/10.1101/GAD.282400.116/-/DC1CrossRef

98.

Jiang, W., Pang, X.-G., Wang, Q., Shen, Y.-X., Chen, X.-K., & Xi, J.-J. (2012). Prognostic role of Twist, Slug, and Foxc2 expression in stage I non–small-cell lung cancer after curative resection. Clinical Lung Cancer, 13(4), 280–287. https://doi.org/10.1016/j.cllc.2011.11.005CrossRef

99.

Sasahira, T., Ueda, N., Yamamoto, K., Kurihara, M., Matsushima, S., Bhawal, U. K., et al. (2014). Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma. PLoS ONE, 9(3), e92534. https://doi.org/10.1371/journal.pone.0092534CrossRef

100.

Pereira, E. R., Kedrin, D., Seano, G., Gautier, O., Meijer, E. F. J., Jones, D., P., et al. (2018). Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science, 359(6382), 1403–1407. https://doi.org/10.1126/science.aal3622CrossRef

101.

Brown, M., Assen, F. P., Leithner, A., Abe, J., Schachner, H., Asfour, G., et al. (2018). Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science, 359(6382), 1408–1411. https://doi.org/10.1126/science.aal3662CrossRef

102.

Kim, J. K., Kim, H. J., Park, S. Y., Cederberg, A., Westergren, R., Nilsson, D., et al. (2005). Adipocyte-specific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance. Diabetes, 54(6), 1657–1663. https://doi.org/10.2337/DIABETES.54.6.1657CrossRef

103.

Håkansson, J., Eliasson, B., Smith, U., & Enerbäck, S. (2011). Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. Diabetology and Metabolic Syndrome, 3(1), 1–9. https://doi.org/10.1186/1758-5996-3-32/FIGURES/4CrossRef

104.

Nian, X., Zhang, X., Wang, Y., Li, H., Li, J., Liu, H., & Qin, L. (2016). Correlations of FOXC2 gene expression and polymorphism with type 2 diabetes mellitus. Clinical Laboratory, 62(5), 781–791. https://doi.org/10.7754/CLIN.LAB.2015.150729CrossRef

105.

Peng, Y. H., Wang, P., He, X. Q., Hong, M. Z., & Liu, F. (2022). Micro ribonucleic acid-363 regulates the phosphatidylinositol 3-kinase/threonine protein kinase axis by targeting NOTCH1 and forkhead box C2, leading to hepatic glucose and lipids metabolism disorder in type 2 diabetes mellitus. Journal of Diabetes Investigation, 13(2), 236–248. https://doi.org/10.1111/JDI.13695CrossRef

106.

Lidell, M. E., Seifert, E. L., Westergren, R., Heglind, M., Gowing, A., Sukonina, V., et al. (2011). The adipocyte-expressed forkhead transcription factor Foxc2 regulates metabolism through altered mitochondrial function. Diabetes, 60(2), 427–435. https://doi.org/10.2337/DB10-0409CrossRef

107.

Gan, L., Liu, Z., Chen, Y., Luo, D., Feng, F., Liu, G., & Sun, C. (2016). α-MSH and Foxc2 promote fatty acid oxidation through C/EBPβ negative transcription in mice adipose tissue. Scientific Reports, 6(1), 36661. https://doi.org/10.1038/srep36661CrossRef

108.

Ma, Y., Temkin, S. M., Hawkridge, A. M., Guo, C., Wang, W., Wang, X. Y., & Fang, X. (2018). Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Letters, 435, 92–100. https://doi.org/10.1016/J.CANLET.2018.08.006CrossRef

109.

DeBerardinis, R. J., & Chandel, N. S. (2016). Fundamentals of cancer metabolism. Science. Advances, 2(5), e1600200. https://doi.org/10.1126/sciadv.1600200CrossRef

110.

Song, L., Tang, H., Liao, W., Luo, X., Li, Y., Chen, T., & Zhang, X. (2017). FOXC2 positively regulates YAP signaling and promotes the glycolysis of nasopharyngeal carcinoma. Experimental Cell Research, 357(1), 17–24. https://doi.org/10.1016/j.yexcr.2017.04.019CrossRef

111.

Ramirez-Peña, E., Arnold, J., Shivakumar, V., Joseph, R., Vidhya Vijay, G., den Hollander, P., … Mani, S. A. (2019). The epithelial to mesenchymal transition promotes glutamine independence by suppressing GLS2 expression. Cancers, 11(10), 1610. https://doi.org/10.3390/cancers11101610

112.

Liu, M., Zhong, J., Zeng, Z., Huang, K., Ye, Z., Deng, S., et al. (2019). Hypoxia-induced feedback of HIF-1α and lncRNA-CF129 contributes to pancreatic cancer progression through stabilization of p53 protein. Theranostics, 9(16), 4795–4810. https://doi.org/10.7150/THNO.30988CrossRef

113.

Robey, I. F., Lien, A. D., Welsh, S. J., Baggett, B. K., & Gillies, R. J. (2005). Hypoxia-inducible factor-1α and the glycolytic phenotype in tumors. Neoplasia, 7(4), 324. https://doi.org/10.1593/NEO.04430CrossRef

114.

Yang, L., Li, T., & Zha, L. (2020). Foxc2 alleviates ox-LDL-induced lipid accumulation, inflammation, and apoptosis of macrophage via regulating the expression of Angptl2. Inflammation, 43(4), 1397–1410. https://doi.org/10.1007/S10753-020-01217-WCrossRef

115.

Wang, R., Wu, Y., & Jiang, S. (2021). FOXC2 alleviates myocardial ischemia-reperfusion injury in rats through regulating Nrf2/HO-1 signaling pathway. Disease Markers, 2021, 9628521. https://doi.org/10.1155/2021/9628521CrossRef

116.

Hargadon, K. M., & Williams, C. J. (2020). RNA-seq analysis of wild-type vs. FOXC2-deficient melanoma cells reveals a role for the FOXC2 transcription factor in the regulation of multiple oncogenic pathways. Frontiers in Oncology, 10, 267. https://doi.org/10.3389/fonc.2020.00267

117.

Saxena, M., Stephens, M. A., Pathak, H., & Rangarajan, A. (2011). Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death and Disease, 2(7), e179. https://doi.org/10.1038/cddis.2011.61CrossRef

118.

Zhou, Z., Zhang, L., Xie, B., Wang, X., Yang, X., Ding, N., et al. (2015). FOXC2 promotes chemoresistance in nasopharyngeal carcinomas via induction of epithelial mesenchymal transition. Cancer Letters, 363(2), 137–145. https://doi.org/10.1016/j.canlet.2015.04.008CrossRef

119.

Cai, J., Tian, A.-X., Wang, Q.-S., Kong, P.-Z., Du, X., Li, X.-Q., & Feng, Y.-M. (2015). FOXF2 suppresses the FOXC2-mediated epithelial–mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Letters, 367(2), 129–137. https://doi.org/10.1016/j.canlet.2015.07.001CrossRef

120.

He, Y., Xie, H., Yu, P., Jiang, S., & Wei, L. (2018). FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology, 82(6), 1049–1059. https://doi.org/10.1007/s00280-018-3697-2CrossRef

121.

Hargadon, K. M. (2020). Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. Clinical and Translational Medicine, 10(1), 374–411. https://doi.org/10.1002/ctm2.37CrossRef

122.

Norrmén, C., Ivanov, K. I., Cheng, J., Zangger, N., Delorenzi, M., Jaquet, M., et al. (2009). FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. The Journal of Cell Biology, 185(3), 439–457. https://doi.org/10.1083/JCB.200901104CrossRef

123.

Richards, A. L., Eckhardt, M., & Krogan, N. J. (2021). Mass spectrometry-based protein-protein interaction networks for the study of human diseases. Molecular Systems Biology, 17(1), e8792. https://doi.org/10.15252/MSB.20188792

124.

Bushweller, J. H. (2019). Targeting transcription factors in cancer—from undruggable to reality. Nature Reviews Cancer, 19(11), 611–624. https://doi.org/10.1038/s41568-019-0196-7CrossRef

125.

Castaneda, M., Chen, L., Pradhan, L., Li, S., Zein, R., Lee, Y., et al. (2018). A forkhead box protein C2 inhibitor: Targeting epithelial-mesenchymal transition and cancer metastasis. ChemBioChem, 19(13), 1359–1364. https://doi.org/10.1002/cbic.201800022CrossRef

126.

El-Ashmawy, N. E., El-Zamarany, E. A., Khedr, N. F., Selim, H. M., & Khedr, E. G. (2021). Inhibition of PKC/MEK pathway suppresses β1-integrin and mitigates breast cancer cells proliferation. Toxicology Reports, 8, 1530–1537. https://doi.org/10.1016/J.TOXREP.2021.07.012CrossRef

127.

Gong, L., Zhang, Y., Liu, C., Zhang, M., & Han, S. (2021). Application of radiosensitizers in cancer radiotherapy. International Journal of Nanomedicine, 16, 1083–1102. https://doi.org/10.2147/IJN.S290438CrossRef

128.

Imayama, N., Yamada, S.-I., Yanamoto, S., Naruse, T., Matsushita, Y., Takahashi, H., et al. (2015). FOXC2 expression is associated with tumor proliferation and invasion potential in oral tongue squamous cell carcinoma. Pathology Oncology Research, 21(3), 783–791. https://doi.org/10.1007/s12253-014-9891-6CrossRef

129.

Galván, J. A., Astudillo, A., Vallina, A., Crespo, G., Folgueras, M. V., & González, M. V. (2014). Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors. BMC Cancer, 14(1), 855. https://doi.org/10.1186/1471-2407-14-855CrossRef

130.

Ma, L., Yang, R., Gu, J., Jiang, H., & Li, H. (2020). The expression of AGGF1, FOXC2, and E-cadherin in esophageal carcinoma and their clinical significance. Medicine, 99(37), e22173. https://doi.org/10.1097/MD.0000000000022173CrossRef

131.

Sun, Y., Wang, X., Wen, H., Zhu, B., & Yu, L. (2021). Expression and clinical significance of the NCAPH, AGGF1, and FOXC2 proteins in serous ovarian cancer. Cancer Management and Research, 13, 7253–7262. https://doi.org/10.2147/CMAR.S329688CrossRef

132.

Sun, T.-Y., Xie, H.-J., & Kong, L.-F. (2015). Expression of FOXC2 in renal cell carcinoma and its relationship to clinical pathological features. International Journal of Clinical and Experimental Medicine, 8(8), 13388–13392. https://pubmed.ncbi.nlm.nih.gov/26550271/

133.

Zhu, Q., Tang, M., & Wu, L. (2020). Expression of combined interference of slug and FoxC2 in endometrial carcinoma and its clinicopathological relationship. Translational Cancer Research, 9(9), 5268–5280. https://doi.org/10.21037/TCR-20-809

134.

Seo, S., Fujita, H., Nakano, A., Kang, M., Duarte, A., & Kume, T. (2006). The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Developmental Biology, 294(2), 458–470. https://doi.org/10.1016/j.ydbio.2006.03.035CrossRef

135.

Xia, S., Yu, W., Menden, H., Younger, S. T., & Sampath, V. (2021). FOXC2 autoregulates its expression in the pulmonary endothelium after endotoxin stimulation in a histone acetylation-dependent manner. Frontiers in Cell and Developmental Biology, 9, 657662. https://doi.org/10.3389/FCELL.2021.657662CrossRef

Title: Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective
Authors: Kristian M. Hargadon
Travis B. Goodloe III
Nathaniel D. Lloyd
Publication date: 14-06-2022
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10045-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

The vulnerable primed cancer stem cells in disguise: demystifying the role of Maspin

Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression

p73 isoforms meet evolution of metastasis

The multifaceted mechanisms of malignant glioblastoma progression and clinical implications

Message in the bottle: regulation of the tumor microenvironment via exosome-driven proteolysis

Increasing cancer permeability by photodynamic priming: from microenvironment to mechanotransduction signaling

Keynote webinar | Spotlight on antibody–drug conjugates in cancer